vs
Lifeway Foods, Inc.（LWAY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Lifeway Foods, Inc.的季度营收约是REGENXBIO Inc.的1.8倍（$55.4M vs $30.3M），Lifeway Foods, Inc.净利率更高（4.6% vs -221.3%，领先225.9%），REGENXBIO Inc.同比增速更快（43.0% vs 18.0%），Lifeway Foods, Inc.自由现金流更多（$-17.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.4%）
来福威食品公司是一家总部位于美国伊利诺伊州的健康食品企业，成立于1986年，是美国业内领先的开菲尔发酵益生菌产品供应商，这类产品主要用于调节人体微生物群平衡。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LWAY vs RGNX — 直观对比
营收规模更大
LWAY
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出25.0%
18.0%
净利率更高
LWAY
高出225.9%
-221.3%
自由现金流更多
LWAY
多$35.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
11.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.4M | $30.3M |
| 净利润 | $2.5M | $-67.1M |
| 毛利率 | 27.8% | — |
| 营业利润率 | 6.8% | -190.0% |
| 净利率 | 4.6% | -221.3% |
| 营收同比 | 18.0% | 43.0% |
| 净利润同比 | 1688.1% | -31.2% |
| 每股收益（稀释后） | $0.15 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LWAYRGNX
| Q4 25 | $55.4M | $30.3M | ||
| Q3 25 | $57.1M | $29.7M | ||
| Q2 25 | $53.9M | $21.4M | ||
| Q1 25 | $46.1M | $89.0M | ||
| Q4 24 | $46.9M | $21.2M | ||
| Q3 24 | $46.1M | $24.2M | ||
| Q2 24 | $49.2M | $22.3M | ||
| Q1 24 | $44.6M | $15.6M |
净利润LWAYRGNX
| Q4 25 | $2.5M | $-67.1M | ||
| Q3 25 | $3.5M | $-61.9M | ||
| Q2 25 | $4.2M | $-70.9M | ||
| Q1 25 | $3.5M | $6.1M | ||
| Q4 24 | $-160.0K | $-51.2M | ||
| Q3 24 | $3.0M | $-59.6M | ||
| Q2 24 | $3.8M | $-53.0M | ||
| Q1 24 | $2.4M | $-63.3M |
毛利率LWAYRGNX
| Q4 25 | 27.8% | — | ||
| Q3 25 | 28.7% | — | ||
| Q2 25 | 28.6% | — | ||
| Q1 25 | 23.9% | — | ||
| Q4 24 | 25.3% | 70.2% | ||
| Q3 24 | 25.7% | 48.8% | ||
| Q2 24 | 27.0% | 52.5% | ||
| Q1 24 | 25.8% | 72.6% |
营业利润率LWAYRGNX
| Q4 25 | 6.8% | -190.0% | ||
| Q3 25 | 8.8% | -176.3% | ||
| Q2 25 | 10.8% | -296.3% | ||
| Q1 25 | 3.4% | 13.6% | ||
| Q4 24 | 1.5% | -242.1% | ||
| Q3 24 | 9.1% | -256.6% | ||
| Q2 24 | 11.0% | -251.3% | ||
| Q1 24 | 8.0% | -408.8% |
净利率LWAYRGNX
| Q4 25 | 4.6% | -221.3% | ||
| Q3 25 | 6.2% | -208.3% | ||
| Q2 25 | 7.9% | -331.8% | ||
| Q1 25 | 7.7% | 6.8% | ||
| Q4 24 | -0.3% | -241.3% | ||
| Q3 24 | 6.5% | -246.3% | ||
| Q2 24 | 7.7% | -237.7% | ||
| Q1 24 | 5.4% | -405.4% |
每股收益（稀释后）LWAYRGNX
| Q4 25 | $0.15 | $-1.30 | ||
| Q3 25 | $0.23 | $-1.20 | ||
| Q2 25 | $0.28 | $-1.38 | ||
| Q1 25 | $0.23 | $0.12 | ||
| Q4 24 | $0.00 | $-0.99 | ||
| Q3 24 | $0.19 | $-1.17 | ||
| Q2 24 | $0.25 | $-1.05 | ||
| Q1 24 | $0.16 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $85.8M | $102.7M |
| 总资产 | $105.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LWAYRGNX
| Q4 25 | $5.6M | $230.1M | ||
| Q3 25 | $23.0M | $274.2M | ||
| Q2 25 | $21.2M | $323.3M | ||
| Q1 25 | $19.4M | $267.9M | ||
| Q4 24 | $16.7M | $234.7M | ||
| Q3 24 | $20.6M | $255.5M | ||
| Q2 24 | $14.6M | $290.4M | ||
| Q1 24 | $12.0M | $338.7M |
总债务LWAYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.5M | — |
股东权益LWAYRGNX
| Q4 25 | $85.8M | $102.7M | ||
| Q3 25 | $82.8M | $161.5M | ||
| Q2 25 | $78.7M | $213.7M | ||
| Q1 25 | $74.2M | $274.2M | ||
| Q4 24 | $71.9M | $259.7M | ||
| Q3 24 | $71.5M | $301.4M | ||
| Q2 24 | $68.0M | $348.3M | ||
| Q1 24 | $63.5M | $390.7M |
总资产LWAYRGNX
| Q4 25 | $105.6M | $453.0M | ||
| Q3 25 | $109.5M | $525.2M | ||
| Q2 25 | $98.3M | $581.0M | ||
| Q1 25 | $93.7M | $490.9M | ||
| Q4 24 | $90.5M | $466.0M | ||
| Q3 24 | $91.3M | $519.1M | ||
| Q2 24 | $84.9M | $569.4M | ||
| Q1 24 | $82.8M | $629.2M |
负债/权益比LWAYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $267.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-17.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | -31.5% | -174.0% |
| 资本支出强度资本支出/营收 | 31.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.11× | — |
| 过去12个月自由现金流最近4个季度 | $-16.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LWAYRGNX
| Q4 25 | $267.0K | $-52.3M | ||
| Q3 25 | $6.9M | $-56.0M | ||
| Q2 25 | $3.9M | $-49.3M | ||
| Q1 25 | $-150.0K | $33.6M | ||
| Q4 24 | $-2.6M | $-31.6M | ||
| Q3 24 | $7.5M | $-40.5M | ||
| Q2 24 | $6.5M | $-45.5M | ||
| Q1 24 | $1.5M | $-55.5M |
自由现金流LWAYRGNX
| Q4 25 | $-17.4M | $-52.8M | ||
| Q3 25 | $1.8M | $-56.5M | ||
| Q2 25 | $1.6M | $-49.7M | ||
| Q1 25 | $-2.4M | $32.6M | ||
| Q4 24 | $-3.8M | $-32.7M | ||
| Q3 24 | $5.9M | $-40.9M | ||
| Q2 24 | $5.1M | $-46.0M | ||
| Q1 24 | $-923.0K | $-56.0M |
自由现金流率LWAYRGNX
| Q4 25 | -31.5% | -174.0% | ||
| Q3 25 | 3.1% | -189.9% | ||
| Q2 25 | 3.0% | -232.8% | ||
| Q1 25 | -5.1% | 36.6% | ||
| Q4 24 | -8.2% | -154.2% | ||
| Q3 24 | 12.8% | -168.9% | ||
| Q2 24 | 10.4% | -206.2% | ||
| Q1 24 | -2.1% | -358.5% |
资本支出强度LWAYRGNX
| Q4 25 | 31.9% | 1.7% | ||
| Q3 25 | 9.0% | 1.7% | ||
| Q2 25 | 4.3% | 1.8% | ||
| Q1 25 | 4.8% | 1.2% | ||
| Q4 24 | 2.7% | 5.1% | ||
| Q3 24 | 3.3% | 1.3% | ||
| Q2 24 | 2.9% | 2.1% | ||
| Q1 24 | 5.5% | 3.6% |
现金转化率LWAYRGNX
| Q4 25 | 0.11× | — | ||
| Q3 25 | 1.96× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | -0.04× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.50× | — | ||
| Q2 24 | 1.73× | — | ||
| Q1 24 | 0.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LWAY
| Drinkable Kefirotherthan Pro Bugs | $47.8M | 86% |
| Cheese | $4.7M | 8% |
| Cream And Other | $1.7M | 3% |
| Other | $1.2M | 2% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
